Bellicum Pharmaceuticals Announces Appointment of Judith Klimovsky, M.D., to Board of Directors
December 20 2018 - 07:00AM
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in
developing novel, controllable cellular immunotherapies for cancers
and orphan inherited blood disorders, today announced the
appointment of Judith Klimovsky, M.D., to its board of directors
effective December 20, 2018. Dr. Klimovsky currently serves as the
Executive Vice President & Chief Development Officer of Genmab,
an international biotechnology company developing antibody
therapeutics for cancer, where she leads the company’s product
development efforts. She is replacing Frank McGuyer, who resigned
from the board effective December 20, 2018. Mr. McGuyer served as a
member of the board for nine years.
“We are pleased to welcome Judith to our board of directors; she
brings to the board extensive leadership experience in drug
development—particularly in our key focus areas of oncology and
hematology. We’re looking forward to working closely with Judith as
we continue to advance and expand our pipeline of controllable cell
immunotherapies,” said Bellicum’s President & CEO Rick Fair.
“We would also like to acknowledge and thank Frank McGuyer, who is
stepping down as a director, for his many years of distinguished
service to our Company.”
Dr. Klimovsky has more than 15 years of experience in product
strategy, drug development and medical affairs for the biotech and
pharmaceutical industry. Prior to joining Genmab, she held
successively senior positions at Bristol-Myers Squibb, Merck and
Novartis and led or contributed to the clinical development of key
cancer drugs, including ixabepilone (BMS), MEK162, LGX818 and
Afinitor (Novartis). Previously, Dr. Klimovsky served in
various hematology clinical practice positions in Buenos Aires,
Argentina. Dr. Klimovsky earned her M.D. from the Buenos Aires
University School of Medicine.
About Bellicum Pharmaceuticals Bellicum is
a clinical stage biopharmaceutical company striving to deliver
cures through controllable cell therapies. The Company’s
next-generation product candidates are differentiated by powerful
cell signaling technologies designed to produce more effective
CAR-T, TCR and allogeneic T cell therapies. Its lead product
candidate, rivo-celTM, is an allogeneic polyclonal T cell therapy
that has shown promising clinical trial results in reducing
leukemia relapse after a stem cell transplant. Bellicum’s lead
GoCAR-T® candidate, BPX-601, is designed to be a more efficacious
CAR-T cell product capable of overriding key immune inhibitory
mechanisms. More information can be found
at www.bellicum.com.
Forward-Looking Statement
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things:
the anticipated benefits of Dr. Klimovsky’s appointment to our
Board; our plans to advance and expand our pipeline of controllable
cell immunotherapies; our research and development activities
relating to our polyclonal T cell, CAR-T and TCR programs; our
pipeline candidate’s effectiveness, possible ranges of application
and potential safety and curative effects in the treatment of
diseases, including as compared to other treatment options and
competitive therapies; and the timing and success of our current
and planned clinical trials. Various factors may cause differences
between Bellicum’s expectations and actual results as discussed in
greater detail under the heading “Risk Factors” in Bellicum’s
filings with the Securities and Exchange Commission, including
without limitation our quarterly report on Form 10-Q for the three
months ended September 30, 2018 and our annual report on Form 10-K
for the year ended December 31, 2017. Any forward-looking
statements that Bellicum makes in this press release speak only as
of the date of this press release. Bellicum assumes no obligation
to update our forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
Source: Bellicum Pharmaceuticals
Investors:
Solebury Trout
Chad Rubin
646-378-2947
crubin@soleburytrout.com
Media:
Solebury Trout
Brad Miles
646-513-3125
bmiles@troutgroup.com
Source: Bellicum Pharmaceuticals
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Mar 2023 to Mar 2024